BiondVax Pharmaceuticals Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net income was ILS 3.75 million compared to net loss of ILS 9.05 million a year ago. Basic earnings per share from continuing operations was ILS 4 compared to basic loss per share from continuing operations of ILS 8 a year ago.
For the nine months, net loss was ILS 18.52 million compared to ILS 29.23 million a year ago. Basic loss per share from continuing operations was ILS 8 compared to ILS 20 a year ago.